Phase 2 Rare Disease Trial, Recruiting (NCT07117890)

Phase 2 Rare Disease Trial, Recruiting NCT07117890 Sponsor: Fudan University Condition: Rare Disease

Printed from Voxsanity (voxsanity.com.au) — NCT07117890 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Rare Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You must be 18 years of age or older.
You must have a confirmed diagnosis of a specific type of lung cancer (non-squamous non-small cell lung cancer) with particular genetic changes called "EGFR uncommon mutations," verified by a lab test — this includes at least one uncommon EGFR mutation, but excludes certain common ones (confirm with trial site if unsure which type you have).
Your doctor expects you to live for at least 12 weeks or more.
Your cancer must be measurable on scans, meaning doctors can track its size using standard imaging guidelines.

Who may not be able to join:

You have previously received any systemic treatment (such as chemotherapy or targeted therapy) for your cancer.
You have had another type of cancer diagnosed within the last 2 years.
You have a serious or hard-to-control health condition, as judged by the trial doctor (confirm with trial site).
You currently have an active infection of any kind.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 18017312369

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07117890

Sponsor: Fudan University

Phase: Phase 2

Status: Recruiting

Condition: Rare Disease

Trial contact: 18017312369

More information: https://clinicaltrials.gov/study/NCT07117890

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You must be 18 years of age or older.
You must have a confirmed diagnosis of a specific type of lung cancer (non-squamous non-small cell lung cancer) with particular genetic changes called "EGFR uncommon mutations," verified by a lab test — this includes at least one uncommon EGFR mutation, but excludes certain common ones (confirm with trial site if unsure which type you have).
Your doctor expects you to live for at least 12 weeks or more.
Your cancer must be measurable on scans, meaning doctors can track its size using standard imaging guidelines.

Who may not be able to join:

You have previously received any systemic treatment (such as chemotherapy or targeted therapy) for your cancer.
You have had another type of cancer diagnosed within the last 2 years.
You have a serious or hard-to-control health condition, as judged by the trial doctor (confirm with trial site).
You currently have an active infection of any kind.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Fudan University

Registry

ClinicalTrials.gov

Start date

7 February 2025

Est. completion

20 February 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Objective Response Rate(ORR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov